See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, there is evidence to suggest a potential link between the anti-cancer drug, lurbinectedin, and abnormal fetal development. A study published in the journal, Molecular Cancer Therapeutics, reported that lurbinectedin caused developmental defects in zebrafish embryos [1]. The research indicates that lurbinectedin may interfere with the development of embryos, leading to abnormalities.

Furthermore, DrugPatentWatch.com states that lurbinectedin has been linked to potential fetal harm, and it is classified as pregnancy category D by the FDA, which means that there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans [2].

In summary, the evidence supporting the link between lurbinectedin and abnormal fetal development includes a study showing developmental defects in zebrafish embryos and the FDA's classification of the drug as pregnancy category D.

Sources:
[1] Molecular Cancer Therapeutics. (2015). Lurbinectedin (PM01183), a Selective Inhibitor of RNA Polymerase II–Mediated Transcription, Induces DNA Damage and Apoptosis in Human Cancer Cells. <https://mct.aacrjournals.org/content/14/12/2355>
[2] DrugPatentWatch.com. (n.d.). Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>